The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study

Kyeong A So; Mi Jung Kim; Ki-Heon Lee; In-Ho Lee; Mi Kyung Kim; Yoo Kyung Lee; Chang-Sun Hwang; Mi Seon Jeong; Mee-Kyung Kee; Chun Kang; Chi Heum Cho; Seok Mo Kim; Sung Ran Hong; Ki Tae Kim; Won-Chul Lee; Jong Sup Park; Tae Jin Kim

doi:10.4143/crt.2016.013

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(4); 2016 > Article

Original Article The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study: Kyeong A So, MD, PhD¹, Mi Jung Kim, MD¹, Ki-Heon Lee, MD, PhD¹, In-Ho Lee, MD, PhD¹, Mi Kyung Kim, MD, PhD¹, Yoo Kyung Lee, MD, PhD¹, Chang-Sun Hwang, PhD¹, Mi Seon Jeong, BS¹, Mee-Kyung Kee, PhD², Chun Kang, MS², Chi Heum Cho, MD, PhD³, Seok Mo Kim, MD, PhD⁴, Sung Ran Hong, MD, PhD⁵, Ki Tae Kim, MD, PhD⁶, Won-Chul Lee, MD, PhD⁷, Jong Sup Park, MD, PhD^8,, Tae Jin Kim, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(4):1313-1320.
DOI: https://doi.org/10.4143/crt.2016.013
Published online: March 9, 2016

¹Department of Obstetrics and Gynecology, Cheil General Hospital and Women’s Healthcare Center, Dankook University College of Medicine, Seoul, Korea

²Division of AIDS, Center for Immunology and Pathology, National Institute of Health, Korea Centers for Disease Control and Prevention, Cheongwon, Korea

³Department of Obstetrics and Gynecology, Keimyung University Dongsan Medical Center, Daegu, Korea

⁴Department of Obstetrics and Gynecology, Chonnam National University Medical School, Gwangju, Korea

⁵Department of Pathology, Cheil General Hospital and Women’s Healthcare Center, Dankook University College of Medicine, Seoul, Korea

⁶Department of Obstetrics and Gynecology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

⁷Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

⁸Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence: Tae Jin Kim, MD, PhD Department of Obstetrics and Gynecology, Cheil General Hospital and Women’s Healthcare Center, Dankook University College of Medicine, 17 Seoae-ro 1-gil, Jung-gu, Seoul 04619, Korea
Tel: 82-2-2000-7577 Fax: 82-2-2000-7477 E-mail: kimonc111@naver.com

Co-Correspondence: Jong Sup Park, MD, PhD Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea
Tel: 82-2-2258-7592 Fax: 82-2-2258-2724 E-mail: jspark@catholic.ac.kr

*Kyeong A So and Mi Jung Kim contributed equally to this work.

• Received: January 7, 2016 • Accepted: February 29, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

33,609 Views
299 Download
16 Web of Science
16 Crossref
18 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
The purpose of this study is to evaluate the impact of high-risk human papillomaviruses (HPVs) other than HPV 16/18 on the natural course of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL).
Materials and Methods
The study population was derived from the Korean HPV cohort (2010-2014). Women aged 20 to 60 who satisfied the criteria of having both HPV infection and abnormal cervical cytology of either ASC-US or LSIL were recruited from five institutions nationwide. Enrolled patients underwent cervical cytology and HPV DNA testing every 6 months.
Results
A total of 1,158 patients were enrolled. The 10 most common HPV types were HPV 16 (12.3%), 58 (10.0%), 56 (8.8%), 53 (8.4%), 52 (7.7%), 39 (6.2%), 18 (6.0%), 51 (5.7%), 68 (5.1%), and 66 (4.6%). Among these patients, 636 women were positive for high-risk HPVs other than HPV 16 or 18, and 429 women were followed for more than 6 months. Cytology evaluations showed progression in 15.3% of women, no change in 22.6%, and regression in 62.1% of women at 12 months. In cases of HPV 58 single infection, a more highly significant progression rate, compared to other high-risk types, was observed at 6 months (relative risk [RR], 3.3; 95% confidence interval [CI], 2.04 to 5.30; p < 0.001) and 12 months (RR, 5.03; 95% CI, 2.56 to 9.91; p < 0.001).
Conclusion
HPV genotypes numbered in the 50s were frequent in Korean women with ASC-US and LSIL. HPV 58 was the second most common type, with a high progression rate of cervical cytology.
Key words: Human papillomavirus, Genotype, Cytology

Introduction

More than 100 human papillomaviruses (HPVs) have been identified, among which approximately 20 types are known as high-risk or oncogenic types [1]. High-risk HPVs are the most important contributors to the development of cervical precancerous lesions and invasive carcinomas. The prevalence of cervical cancer varies remarkably in different countries; this is mainly related to the availability of cervical cancer screening programs [2]. In Korea, despite a decrease in cervical cancer incidence from 1999 to 2012 because of an organized screening program, it is still predicted to be the seventh most common female cancer with 3,100 new cases and the third most common cancer in women aged 15 to 34 in 2015 [3-5].

Persistent infection with high-risk HPVs is a primary risk factor for cervical carcinogenesis. Among the high-risk HPVs, HPV 16 and HPV 18 are the two most carcinogenic genotypes and current prophylactic vaccines against HPV 16/18 may prevent up to 70% of cervical cancers [6]. High-risk HPVs other than HPV 16/18 cause the remaining 25%-35% of cervical cancers [7]. Globally, the most common genotypes other than HPV 16/18, in descending order of frequency are: HPV 45, 31, 33, 52, 58, and 35 [8]. However, there is considerable geographical variation in the prevalence of these HPV types. The prevalence of other high-risk HPV types is higher in Asia, Africa, and South/Central America (30%-35%) than in Europe, Oceania, and North America (23%-26%) [7]. Clarification of the contributions of individual genotypes causing cervical carcinogenesis will be important in order to provide an estimate of the potential impact of prophylactic vaccines and cancer screening programs.

This is a prospective study in a Korean HPV cohort [9]. The aims of this study were first to evaluate the distributional proportions along the full spectrum of high-risk HPVs in a Korean HPV cohort, and second, to determine the natural progression of atypical squamous cells of unknown significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) with high-risk HPV infections other than HPV 16/18.

Materials and Methods

A Korean HPV cohort study was conducted between April 2010 and October 2014. The HPV cohort recruited women aged 20 to 60 who satisfied both criteria of HPV positivity and abnormal cervical cytology of either ASC-US or LSIL from five institutions nationwide. Exclusion criteria included any of the following: previous hysterectomy, history of cervical intraepithelial neoplasia (CIN) treated within 6 months, pregnancy, coexisting malignancies, and psychological diseases currently under treatment. The study was approved by the institutional review board and informed consent was obtained from each participant prior to the study.

Enrolled patients underwent cervical liquid-based cytology and HPV DNA testing every 6 months. Cytological progression was defined as the change to atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (HSIL), HSIL, and LSIL from ASC-US, or as the change to HSIL from LSIL. Regression was defined as the change to normal cytology or ASC-US from LSIL, or to normal cytology from ASC-US. The others were categorized as no change. Colposcopy-directed biopsies were performed in patients with cytologic results indicative of conditions worse than HSIL. Patients diagnosed as having a lesion classified as greater than CIN 2 by colposcopy-directed biopsy were terminated in this study. Cervical samples were collected using a Cervex-Brush (Rovers Medical Devices, Oss, Netherlands) from cervical os and SurePath liquid-based cytology (TriPath Imaging, Inc., Burlington, NC) was used during the follow-up examinations. Cheil General Hospital served as a central laboratory for cytological diagnoses according to the 2001 Bethesda reporting system [10], and HPV genotyping testing during the follow-up examinations. HPV genotyping was performed using a DNA microarray technique with a Cheil HPV DNA Chip Kit (Cheil General Hospital, Seoul, Korea), based on a polymerase chain reaction method. Briefly, post-amplification SYBR Green reverse transcription quantitative polymerase chain reaction products were analyzed by Ct value and hybridized with probes for HPVs. Samples were analyzed for the presence of 19 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68a, 68b, 69, and 82) and 17 low-risk HPV types (6, 11, 30, 32, 40, 42, 43, 44, 54, 55, 62, 70, 72, 81, 84, 90, and 91).

1. Statistical analysis

Data were analyzed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL). Categorical variables were indicated as numbers and percentages. To assess the risk of cytological progression associated with HPV genotypes, relative risk (RR) with 95% confidence intervals (CI) was estimated by chi-square test. All p-values of less than 0.05 were considered statistically significant.

Results

Among a total of 1,158 patients in the Korean HPV cohort study, 636 patients met the eligibility criteria of this study (Fig. 1). ASC-US and LSIL were observed in 360 patients (56.6%) and 276 patients (43.4%), respectively. With respect to follow-up, 429 patients (67.5%) were followed up at 6 months and 301 (47.3%) at 12 months. The prevalence of high-risk HPV infections at the time of enrollment is summarized in Table 1. The most common type of high-risk HPV was type 16 (12.3%) as a single infection (n=85) and multiple infection (n=58). In this cohort, HPV 58 was the second most common type, with 74 patients having a single infection and 42 patients having multiple infections. Only ten patients with HPV 58 were co-infected with HPV 16 or 18. Among the ten most common high-risk HPVs, HPV 58, 56, 53, and 52 ranked as the top five. Cytological changes in patients with high-risk HPV infections other than HPV 16/18 during the follow-up periods are shown in Table 2. The rates of regression, no change, and progression of cervical cytology were 58.0%, 26.1%, and 15.9% at 6 months and 62.1%, 22.6%, and 15.3% at 12 months; 113 of 360 cases of ASC-US (31.4%) had regressed to normal cytology at 6 months; 136 of 276 cases of LSIL (49.3%) had regressed to either ASC-US (n=54) or normal cytology (n=82).

However, 147 of 301 (48.8%) ASC-US/LSIL cases maintained abnormal cytology for 12 months. In the unchanged and progression groups, the persistent rates of high-risk HPV infections other than HPV 16/18 were markedly higher than in the regression group (p < 0.001). Among patients in the progression group, only three patients (4.4%) and one patient (2.2%) were HPV negative by HPV DNA test at 6 and 12 months, respectively. However, in the regression group, HPV infections had cleared in up to 62.6% of patients at the 12-month follow-up.

Analyses of high-risk HPV infections other than HPV 16/18 showed persistence in 41.9%, incidental infection in 24.6%, and clearance in 33.5% of patients at 12 months; 36.5% of the persistent infections were identified as having been caused by the same genotype on all HPV DNA tests. In addition, persistent infection with each HPV genotype showed a significant correlation with the prognosis of cervical cytology. The rates of persistent infection for other high-risk HPVs gradually increased from regression to progression in cytological prognosis (p < 0.001).

With the exception of HPV 16/18, the HPV type-specific prognoses of cervical cytology are shown in Table 3. The cytological progression rates of HPV 58, 56, 53, 52, 39, 51, 68, and 66 single infections were 30.3%, 2.9%, 7.7%, 13.1%, 11.8%, 7.2%, 15.4%, and 5.9%, respectively, at 12 months. Except for HPV 58, low progression rates were observed for the other common HPV types (1.5%-29.3%) in both single and total infections. A relatively high progression rate (26.0%-37.5%) was observed for HPV 58 infection during the follow-up periods. The rate of cytological progression was 27.0% (27 out of 100) in the HPV 16 persistence group, and 9.8% (4 out of 41) in the HPV 18 persistence group at 6 months of follow-up.

According to the genotype and follow-up duration, the RRs to progression of cytology are shown in Table 4. HPV 58 single infection with ASC-US/LSIL resulted in a significantly higher risk of progression, compared with other common high-risk HPVs at 6 and 12 months (RR, 3.30; 95% CI, 2.04 to 5.30; p < 0.001 and RR, 5.03; 95% CI, 2.56 to 9.91; p < 0.001). Type 56, 53, and 52 HPVs, which initially ranked among the top five types, showed no significant RRs.

Discussion

In this study, HPV 16 (12.3%) was clearly the predominant HPV type identified among the 1,158 women with ASC-US or LSIL, consistent with the universal trend among prevalent HPV types. However HPV 18 (6.0%) was not frequent in our study. Instead of HPV 18, HPV 58 (10.0%) was the second most common HPV type. This finding is consistent with those of other previous studies conducted in East Asia. The overall reported prevalence of HPV 58 was 11.4% in a study from Hong Kong [11]. In a study conducted in China, HPV 58 was more frequent than HPV 18 in precancerous lesions (19.1% vs. 5.4%, respectively) and the same infection rates for HPV 58 and HPV 18 were reported in cervical cancers (9.4% each) [12]. HPV 58 accounts for a considerable disease burden in East Asia. Its prevalence in cervical cancer is higher in Asia (5.6%) than in other parts of the world (3.3%) [13]. In a large scale Korean study (n=1,650), HPV 58 was the second most common HPV in LSIL (8.1%) and HSIL (15.7%) [14]. HSIL has also shown a relatively high prevalence (17.2%) of HPV 58 infection in East Asia [15].

The lifelong risk for HPV infection is greater than 70% in sexually active women [16]. Most HPV infections are spontaneously cleared within 1 to 2 years because of immunological mechanisms [17,18]. In a previous study evaluating HPV infections in adolescents, infections were spontaneously cleared by 12 months in over 50% of infections caused by high-risk HPV types and two-thirds of infections caused by low-risk HPV types [19]. In this study, the overall clearance rate of high-risk HPV types other than HPV 16/18 at 12 months was 33.5%. HPV clearance was also higher in the cytological regression group than in the unchanged and progression groups. Overall, approximately 60% of patients showed regression on the subsequent follow-up Papanicolaou tests.

On the other hand, persistence of HPV infection was closely related to the prognosis of cervical cytology. Approximately 15% of patients showed cytological progression on every follow-up test. The progression group showed significantly higher rates of persistent infection with all other high-risk HPV types. Significant decreases in the rates of persistent infection were observed in the cytological regression, the unchanged, and progression groups, in order (p < 0.001). The results of this study with respect to cervical pathogenesis confirm that persistent high-risk HPV infection induces cervical carcinogenesis. In most cases, the persistence of high-risk HPV infection is related to an increased risk of developing precancerous lesion or invasive carcinomas [20]. The persistence of high-risk HPV infection for 1 or 2 years strongly predicts a diagnosis of CIN 2+ in the subsequent years [21,22]. Furthermore, high HPV viral load was significantly associated with lymphovascular space invasion and deep stromal invasion in cervical cancer [23].

In the analysis of type-specific prognoses, HPV 58 resulted in high rates of cytological progression at 6 and 12 months, compared with other high-risk types (RR, 3.30; 95% CI, 2.04 to 5.30; p < 0.001 and RR, 5.03; 95% CI, 2.56 to 9.91; p < 0.001). The reason for the high prevalence of HPV 58 and cervical carcinogenesis in East Asia is not fully understood, but may result from differences in the oncogenic potentials among the high-risk HPV types. Also, the oncogenicity of viral variants and host genetic backgrounds may play roles in the distinct geographical distribution of HPV 58. A multi-step process involving various host factors is needed for development of tumor cells from an HPV-infected epithelium [24]. The prevalence of HPV 58 increases significantly according to the severity of cervical neoplasia, and its variants are epidemiologically associated with a higher oncogenic risk [11]. Four featured variant lineages of HPV 58 (sublineage A1) showing a regional preponderance in Asia, and associated with a higher risk for cervical neoplasia, were recently reported [13,25]. Therefore, the detection of HPV 58 in addition to HPVs 16 and 18 in cytologically abnormal women may provide an early indicator of cervical precancerous lesion and invasive cancers in East Asia. In addition, it may be helpful in predicting the effects of the next generation vaccines for other high-risk HPVs (non–HPV 16/18) [26].

This study was the first Korean HPV cohort study and provided a relatively large-scale assessment of the distribution of HPV types in South Korea. The results showed the impact of HPV genotypes on the natural course of cervical cytology over the course of 1 year. The evaluation of this cohort is ongoing and we will report follow-up data from the longitudinal study.

Conclusion

Overall, HPV genotypes numbered in the 50s were frequent in Korean women with ASC-US and LSIL. In particular, HPV 58 was the most common high-risk HPV other than HPV 16/18 and greatly contributed to cytological progression in women with ASC-US/LSIL. This result may help us to understand the HPV genotype distribution and provide additional information on the association of HPV types other than HPV 16/18 with the prognosis of abnormal cytology.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This study was supported by a fund of the Chronic Infectious Disease Cohort Study (4800-4859-304-260, 2013-E51005-02) from the Korea Centers for Disease Control and Prevention.

Fig. 1.

Flow diagram of study selection. HPV, human papillomavirus; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.

Table 1.

Prevalence of HPVs among women with ASCUS or LSIL

Category	Rank	HPV genotype	No. (%) (n=1,158)
High risk	1	HPV 16	143 (12.3)
	2	HPV 58	116 (10.0)
	3	HPV 56	102 (8.8)
	4	HPV 53	97 (8.4)
	5	HPV 52	89 (7.7)
	6	HPV 39	72 (6.2)
	7	HPV 18	70 (6.0)
	8	HPV 51	66 (5.7)
	9	HPV 68	59 (5.1)
	10	HPV 66	53 (4.6)
	11	HPV 35	41 (3.5)
	12	HPV 33	37 (3.2)
	13	HPV 31	28 (2.4)
	14	HPV 59	24 (2.1)
	15	HPV 45	16 (1.4)
	16	HPV 67	6 (0.5)
	17	HPV 82	5 (0.4)
	18	HPV 69	4 (0.3)
Low risk	1	HPV 70	41 (3.5)
	2	HPV 40	33 (2.8)
	3	HPV 54	28 (2.4)
	4	HPV 44	27 (2.3)
	5	HPV 62	23 (2.0)
	6	HPV 6	22 (1.9)
	7	HPV 81	20 (1.7)
	8	HPV 42	17 (1.5)
	9	HPV 30	16 (1.4)
	10	HPV 43	15 (1.3)
	11	HPV 11, 84	14 (1.2)
	12	HPV 90	11 (0.9)
	13	HPV 91	10 (0.9)
	14	HPV 55	4 (0.3)
	15	HPV 32, 72	1 (0.1)

Each type included single and multiple infection. HPV, human papillomavirus; ASC-US, atypical squamous cell uncertain significance; LSIL, low-grade squamous intraepithelial lesion.

Table 2.

Prevalence of high-risk HPVs infection according to the prognosis of cervical cytology

Category	Regression	No change	Progression	Total	p-value
6 Mo	249 (58.0)	112 (26.1)	68 (15.9)	429 (100)	< 0.001
High-risk HPV (+)	111 (44.6)	93 (83.0)	65 (95.6)	269 (62.7)
High-risk HPV (–)	138 (55.4)	19 (17.0)	3 (4.4)	160 (37.3)
12 Mo	187 (62.1)	68 (22.6)	46 (15.3)	301 (100)	< 0.001
High-risk HPV (+)	70 (37.4)	49 (72.1)	45 (97.8)	164 (54.5)
High-risk HPV (–)	117 (62.6)	19 (27.9)	1 (2.2)	137 (45.5)

Values are presented as number (%). HPV, human papillomavirus.

Table 3.

HPV type-specific prognosis for cervical cytology

HPV genotype	Prognosis of cytology	Single infection		Total infections
HPV genotype	Prognosis of cytology	6 Mo	12 Mo	6 Mo	12 Mo
HPV 58	Progression	18 (37.5)	10 (30.3)	22 (29.7)	13 (26.0)
	No change	10 (20.8)	6 (18.2)	18 (24.3)	12 (24.0)
	Regression	20 (41.7)	17 (51.5)	34 (46.0)	25 (50.0)
HPV 56	Progression	1 (1.8)	1 (2.9)	1 (1.5)	2 (4.2)
	No change	11 (20.0)	2 (5.9)	22 (33.3)	7 (14.6)
	Regression	43 (78.2)	31 (91.2)	43 (65.2)	39 (81.2)
HPV 53	Progression	3 (8.6)	2 (7.7)	6 (9.2)	4 (8.5)
	No change	6 (17.1)	4 (15.4)	13 (20.0)	10 (21.3)
	Regression	26 (74.3)	20 (76.9)	46 (70.8)	33 (70.2)
HPV 52	Progression	6 (17.6)	3 (13.1)	11 (19.3)	12 (29.3)
	No change	11 (32.4)	5 (21.7)	18 (31.6)	9 (21.9)
	Regression	17 (50.0)	15 (65.2)	28 (49.1)	20 (48.8)
HPV 39	Progression	3 (11.5)	2 (11.8)	5 (11.4)	3 (10.7)
	No change	7 (26.9)	5 (29.4)	13 (29.5)	10 (35.7)
	Regression	16 (61.6)	10 (58.8)	26 (59.1)	15 (53.6)
HPV 51	Progression	2 (9.1)	1 (7.2)	5 (11.9)	5 (20.8)
	No change	5 (22.7)	3 (21.4)	14 (33.3)	5 (20.8)
	Regression	15 (68.2)	10 (71.4)	23 (54.8)	14 (58.4)
HPV 68	Progression	4 (23.5)	2 (15.4)	8 (25.0)	5 (22.7)
	No change	4 (23.5)	3 (23.1)	9 (28.1)	5 (22.7)
	Regression	9 (53.0)	8 (61.5)	15 (46.9)	12 (54.6)
HPV 66	Progression	3 (13.6)	1 (5.9)	4 (11.4)	2 (8.0)
	No change	6 (27.3)	5 (29.4)	11 (31.4)	7 (28.0)
	Regression	13 (59.1)	11 (64.7)	20 (57.2)	16 (64.0)

Values are presented as number (%). HPV, human papillomavirus.

Table 4.

HPV type.specific relative risk to progression of cervical cytology

HPV type	6 Mo			12 Mo
HPV type	No.	RR (95% CI)	p-value	No.	RR (95% CI)	p-value
HPV 58	18/48	3.3 (2.04-5.30)	< 0.001	10/24	5.03 (2.56-9.91)	< 0.001
Others	22/211	1		12/153	1
HPV 56	1/55	0.10 (0.14-0.72)	< 0.001	1/14	0.52 (0.07-4.18)	0.458
Others	39/204	1		22/163	1
HPV 53	3/35	0.51 (0.17-1.60)	0.170	2/15	1.08 (0.26-4.49)	0.583
Others	37/224	1		20/162	1
HPV 52	6/33	1.22 (0.54-2.76)	0.401	2/18	0.88 (0.22-3.57)	0.607
Others	34/226	1		20/159	1
HPV 39	3/26	0.71 (0.23-2.27)	0.404	2/10	1.76 (0.40-7.77)	0.360
Others	37/233	1		20/167	1
HPV 51	2/22	0.55 (0.13-2.25)	0.306	1/12	0.64 (0.09-4.72)	0.545
Others	38/237	1		21/165	1
HPV 68	4/17	1.69 (0.58-4.90)	0.257	2/10	1.76 (0.40-7.77)	0.360
Others	36/242	1		20/167	1
HPV 66	3/22	0.86 (0.27-2.80)	0.549	1/28	0.26 (0.04-1.83)	0.100
Others	37/237	1		21/149	1

HPV, human papillomavirus; RR, relative risk; CI, confidence interval.

REFERENCES

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17–27. Article PubMed
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. Article PubMed
3. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41. Article PubMed PMC PDF
4. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee DH, et al. Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat. 2015;47:142–8. Article PubMed PMC PDF
5. Seol HJ, Ki KD, Lee JM. Epidemiologic characteristics of cervical cancer in Korean women. J Gynecol Oncol. 2014;25:70–4. Article PubMed PMC
6. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32. Article PubMed
7. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72. Article PubMed PMC
8. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–85. Article PubMed
9. Lee WC, Lee SY, Koo YJ, Kim TJ, Hur SY, Hong SR, et al. Establishment of a Korea HPV cohort study. J Gynecol Oncol. 2013;24:59–65. Article PubMed PMC
10. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9. Article PubMed
11. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst. 2002;94:1249–53. Article PubMed
12. Hong D, Ye F, Chen H, Lu W, Cheng Q, Hu Y, et al. Distribution of human papillomavirus genotypes in the patients with cervical carcinoma and its precursors in Zhejiang Province, China. Int J Gynecol Cancer. 2008;18:104–9. Article PubMed
13. Li Y, Wang X, Ni T, Wang F, Lu W, Zhu J, et al. Human papillomavirus type 58 genome variations and RNA expression in cervical lesions. J Virol. 2013;87:9313–22. Article PubMed PMC
14. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, et al. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer. 2003;97:1672–80. Article PubMed
15. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer. 2012;131:692–705. Article PubMed
16. Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, et al. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol. 2008;140:245–51. Article PubMed
17. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195:1582–9. Article PubMed
18. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513–7. Article PubMed PMC
19. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182–92. Article PubMed PMC
20. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106:396–403. Article PubMed
21. Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009;339:b2569.Article PubMed PMC
22. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478–88. Article PubMed PMC
23. Deng T, Feng Y, Zheng J, Huang Q, Liu J. Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. J Gynecol Oncol. 2015;26:111–7. Article PubMed PMC
24. Chan PK. Human papillomavirus type 58: the unique role in cervical cancers in East Asia. Cell Biosci. 2012;2:17.Article PubMed PMC
25. Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, et al. Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis. 2011;203:1565–73. Article PubMed PMC
26. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Women 50 Years and Older With Negative Pap Test and Positive Human Papillomavirus Test for Genotypes Other Than 16 and 18—Follow-up Outcomes
Farah S. Baban, Michael R. Henry, Margaret E. Long, Meredith A. VandeHaar, Grant M. Spears, Sarah M. Jenkins, Diva R. Salomao
Journal of Lower Genital Tract Disease.2024; 28(1): 43. CrossRef
Cervical intraepithelial neoplasia in non-16/18 high-risk human papilloma virus positive/cytology negative women: An alternative approach in poor resource areas
Fariba Yarandi, Elham Shirali, Elham Feizabad, Sara Ramhormoziyan, Soheila Sarmadi, Maryam SadrAmeli, Elham Arshadi
Taiwanese Journal of Obstetrics and Gynecology.2023; 62(2): 299. CrossRef
Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer
Fatema Alzahraa Samy Amin, Zeba Un Naher, P. Shaik Syed Ali
Journal of Cancer Research and Clinical Oncology.2023; 149(10): 8077. CrossRef
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
Daniel Sausen, Oren Shechter, Elisa Gallo, Harel Dahari, Ronen Borenstein
Cancers.2023; 15(14): 3692. CrossRef
Association strength of E6 to E6AP/p53 complex correlates with HPV‐mediated oncogenesis risk
Matheus Vitor Ferreira Ferraz, Isabelle Freire Tabosa Viana, Danilo Fernandes Coêlho, Carlos Henrique Bezerra da Cruz, Maíra de Arruda Lima, Madson Allan de Luna Aragão, Roberto Dias Lins
Biopolymers.2022;[Epub] CrossRef
Diagnostic performance of immediate colposcopy among women with high‐risk human papillomavirus (HPV) other than HPV 16/18 and normal cytology
Serdar Aydın, Hande Nur Öncü, Dilek Sema Arıcı
Journal of Obstetrics and Gynaecology Research.2021; 47(2): 720. CrossRef
Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer
Rachelle P. Mendoza, Tahmineh Haidary, Elmer Gabutan, Ying Yin Zhou, Zaheer Bukhari, Courtney Connelly, Wen-Ching Lee, Yi-Chun Lee, Raj Wadgaonkar, Raag Agrawal, M. A. Haseeb, Raavi Gupta
Scientific Reports.2021;[Epub] CrossRef
Distribution of HPV genotypes among women with abnormal cytology results in Alberta, Canada
Sabrina S Plitt, Ryan Kichuk, Sheena Geier, Trenton Smith, Felicia Roy, Alberto Severini, Carmen L Charlton
Journal of the Association of Medical Microbiology and Infectious Disease Canada.2021; 6(2): 94. CrossRef
The Clinical Significance and Utility of HPV-DNA Testing in Korean Women with Atypical Glandular Cells in Cervical Pap Tests: An Analysis of 311 Cases at a Single Institution
Tae-Kyu Jang, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
Cancer Investigation.2021; 39(10): 885. CrossRef
Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study
Jaehyun Seong, Sangmi Ryou, JeongGyu Lee, Myeongsu Yoo, Sooyoung Hur, Byeong-Sun Choi
Virology Journal.2021;[Epub] CrossRef
Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China
Zhiling Wang, Ting Liu, Yunjian Wang, Ying Gu, Hui Wang, Jingkang Liu, Baoxia Cui, Xingsheng Yang
Infectious Agents and Cancer.2020;[Epub] CrossRef
Co-infection between genotypes of the human papillomavirus and Chlamydia trachomatis in Mexican women
Marco A Escarcega-Tame, Marcela López-Hurtado, Marcos R Escobedo-Guerra, Elba Reyes-Maldonado, Graciela Castro-Escarpulli, Fernando M Guerra-Infante
International Journal of STD & AIDS.2020; 31(13): 1255. CrossRef
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach
Giorgio Bogani, Antonino Ditto, Fabio Martinelli, Mauro Signorelli, Valentina Chiappa, Umberto Leone Roberti Maggiore, Francesca Taverna, Claudia Lombardo, Chiara Borghi, Cono Scaffa, Domenica Lorusso, Francesco Raspagliesi
European Journal of Cancer Prevention.2019; 28(2): 81. CrossRef
Human papillomavirus genotype-specific risk in cervical carcinogenesis
Kyeong A So, In Ho Lee, Ki Heon Lee, Sung Ran Hong, Young Jun Kim, Hyun Hee Seo, Tae Jin Kim
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women
Eun Young Ki, Yoon Kyung Lee, Ahwon Lee, Jong Sup Park
Yonsei Medical Journal.2018; 59(5): 662. CrossRef
Genetic variability in E6, E7 and L1 genes of Human Papillomavirus 62 and its prevalence in Mexico
Cristina Artaza-Irigaray, María Guadalupe Flores-Miramontes, Dominik Olszewski, María Teresa Magaña-Torres, María Guadalupe López-Cardona, Yelda Aurora Leal-Herrera, Patricia Piña-Sánchez, Luis Felipe Jave-Suárez, Adriana Aguilar-Lemarroy
Infectious Agents and Cancer.2017;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study

Cancer Res Treat. 2016;48(4):1313-1320. Published online March 9, 2016

DOI: https://doi.org/10.4143/crt.2016.013

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study

Fig. 1. Flow diagram of study selection. HPV, human papillomavirus; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; ASC-H, atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion.

Fig. 1.

The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study

Category	Rank	HPV genotype	No. (%) (n=1,158)
High risk	1	HPV 16	143 (12.3)
	2	HPV 58	116 (10.0)
	3	HPV 56	102 (8.8)
	4	HPV 53	97 (8.4)
	5	HPV 52	89 (7.7)
	6	HPV 39	72 (6.2)
	7	HPV 18	70 (6.0)
	8	HPV 51	66 (5.7)
	9	HPV 68	59 (5.1)
	10	HPV 66	53 (4.6)
	11	HPV 35	41 (3.5)
	12	HPV 33	37 (3.2)
	13	HPV 31	28 (2.4)
	14	HPV 59	24 (2.1)
	15	HPV 45	16 (1.4)
	16	HPV 67	6 (0.5)
	17	HPV 82	5 (0.4)
	18	HPV 69	4 (0.3)
Low risk	1	HPV 70	41 (3.5)
	2	HPV 40	33 (2.8)
	3	HPV 54	28 (2.4)
	4	HPV 44	27 (2.3)
	5	HPV 62	23 (2.0)
	6	HPV 6	22 (1.9)
	7	HPV 81	20 (1.7)
	8	HPV 42	17 (1.5)
	9	HPV 30	16 (1.4)
	10	HPV 43	15 (1.3)
	11	HPV 11, 84	14 (1.2)
	12	HPV 90	11 (0.9)
	13	HPV 91	10 (0.9)
	14	HPV 55	4 (0.3)
	15	HPV 32, 72	1 (0.1)

Category	Regression	No change	Progression	Total	p-value
6 Mo	249 (58.0)	112 (26.1)	68 (15.9)	429 (100)	< 0.001
High-risk HPV (+)	111 (44.6)	93 (83.0)	65 (95.6)	269 (62.7)
High-risk HPV (–)	138 (55.4)	19 (17.0)	3 (4.4)	160 (37.3)
12 Mo	187 (62.1)	68 (22.6)	46 (15.3)	301 (100)	< 0.001
High-risk HPV (+)	70 (37.4)	49 (72.1)	45 (97.8)	164 (54.5)
High-risk HPV (–)	117 (62.6)	19 (27.9)	1 (2.2)	137 (45.5)

HPV genotype	Prognosis of cytology	Single infection		Total infections
HPV genotype	Prognosis of cytology	6 Mo	12 Mo	6 Mo	12 Mo
HPV 58	Progression	18 (37.5)	10 (30.3)	22 (29.7)	13 (26.0)
	No change	10 (20.8)	6 (18.2)	18 (24.3)	12 (24.0)
	Regression	20 (41.7)	17 (51.5)	34 (46.0)	25 (50.0)
HPV 56	Progression	1 (1.8)	1 (2.9)	1 (1.5)	2 (4.2)
	No change	11 (20.0)	2 (5.9)	22 (33.3)	7 (14.6)
	Regression	43 (78.2)	31 (91.2)	43 (65.2)	39 (81.2)
HPV 53	Progression	3 (8.6)	2 (7.7)	6 (9.2)	4 (8.5)
	No change	6 (17.1)	4 (15.4)	13 (20.0)	10 (21.3)
	Regression	26 (74.3)	20 (76.9)	46 (70.8)	33 (70.2)
HPV 52	Progression	6 (17.6)	3 (13.1)	11 (19.3)	12 (29.3)
	No change	11 (32.4)	5 (21.7)	18 (31.6)	9 (21.9)
	Regression	17 (50.0)	15 (65.2)	28 (49.1)	20 (48.8)
HPV 39	Progression	3 (11.5)	2 (11.8)	5 (11.4)	3 (10.7)
	No change	7 (26.9)	5 (29.4)	13 (29.5)	10 (35.7)
	Regression	16 (61.6)	10 (58.8)	26 (59.1)	15 (53.6)
HPV 51	Progression	2 (9.1)	1 (7.2)	5 (11.9)	5 (20.8)
	No change	5 (22.7)	3 (21.4)	14 (33.3)	5 (20.8)
	Regression	15 (68.2)	10 (71.4)	23 (54.8)	14 (58.4)
HPV 68	Progression	4 (23.5)	2 (15.4)	8 (25.0)	5 (22.7)
	No change	4 (23.5)	3 (23.1)	9 (28.1)	5 (22.7)
	Regression	9 (53.0)	8 (61.5)	15 (46.9)	12 (54.6)
HPV 66	Progression	3 (13.6)	1 (5.9)	4 (11.4)	2 (8.0)
	No change	6 (27.3)	5 (29.4)	11 (31.4)	7 (28.0)
	Regression	13 (59.1)	11 (64.7)	20 (57.2)	16 (64.0)

HPV type	6 Mo			12 Mo
HPV type	No.	RR (95% CI)	p-value	No.	RR (95% CI)	p-value
HPV 58	18/48	3.3 (2.04-5.30)	< 0.001	10/24	5.03 (2.56-9.91)	< 0.001
Others	22/211	1		12/153	1
HPV 56	1/55	0.10 (0.14-0.72)	< 0.001	1/14	0.52 (0.07-4.18)	0.458
Others	39/204	1		22/163	1
HPV 53	3/35	0.51 (0.17-1.60)	0.170	2/15	1.08 (0.26-4.49)	0.583
Others	37/224	1		20/162	1
HPV 52	6/33	1.22 (0.54-2.76)	0.401	2/18	0.88 (0.22-3.57)	0.607
Others	34/226	1		20/159	1
HPV 39	3/26	0.71 (0.23-2.27)	0.404	2/10	1.76 (0.40-7.77)	0.360
Others	37/233	1		20/167	1
HPV 51	2/22	0.55 (0.13-2.25)	0.306	1/12	0.64 (0.09-4.72)	0.545
Others	38/237	1		21/165	1
HPV 68	4/17	1.69 (0.58-4.90)	0.257	2/10	1.76 (0.40-7.77)	0.360
Others	36/242	1		20/167	1
HPV 66	3/22	0.86 (0.27-2.80)	0.549	1/28	0.26 (0.04-1.83)	0.100
Others	37/237	1		21/149	1

Table 1. Prevalence of HPVs among women with ASCUS or LSIL

Each type included single and multiple infection. HPV, human papillomavirus; ASC-US, atypical squamous cell uncertain significance; LSIL, low-grade squamous intraepithelial lesion.

Table 2. Prevalence of high-risk HPVs infection according to the prognosis of cervical cytology

Values are presented as number (%). HPV, human papillomavirus.

Table 3. HPV type-specific prognosis for cervical cytology

Values are presented as number (%). HPV, human papillomavirus.

Table 4. HPV type.specific relative risk to progression of cervical cytology